114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
个体化抗抑郁治疗的治疗药物监测
Authors Li Y, Du X, An J, Wu H
Received 10 September 2025
Accepted for publication 18 December 2025
Published 24 December 2025 Volume 2025:19 Pages 11585—11608
DOI https://doi.org/10.2147/DDDT.S566716
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Yan Zhu
Yumeng Li,1,2 Xiaoyu Du,1,2 Jing An,1,2 Huizhen Wu1,2
1Graduate School of Hebei Medical University, Shijiazhuang, Hebei, 050017, People’s Republic of China; 2Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, Hebei, 050051, People’s Republic of China
Correspondence: Huizhen Wu, Email 13582005982@163.com
Objective: This study aimed to establish a UPLC-MS/MS method for the simultaneous quantification of five antidepressants: venlafaxine (VEN) and its metabolite O-desmethylvenlafaxine (ODV), mirtazapine (MIR), sertraline (SER), escitalopram (ESC), and vortioxetine (VTX) in human plasma and saliva. By analyzing real-world therapeutic drug monitoring (TDM) data, this study aimed to identify key factors influencing drug concentrations thereby optimizing personalized treatment strategies for patients with depression and advancing precision medicine.
Methods: Following liquid-liquid extraction for plasma and protein precipitation for saliva, analyte concentrations were determined using a fully validated UPLC-MS/MS method. Validation included assessments of selectivity, linearity, accuracy, precision, extraction recovery, matrix effects, stability, and dilution integrity. The established method was applied to clinical samples, with further investigation into how clinical factors, including age, BMI, renal function (as measured by GFR), total protein (TP), albumin levels, and concomitant medications, influenced the concentration-to-dose ratio (CDR).
Results: The method demonstrated excellent linearity (5– 500 ng/mL) with all validation parameters meeting acceptance criteria. The established method was successfully applied to analyze 566 plasma and 39 saliva samples. TDM revealed significant variations in target attainment rates among different antidepressants, along with varying degrees of dose-concentration correlations. Multivariate analysis demonstrated that the CDR of VEN + ODV was primarily influenced by age and GFR, while the CDR of MIR showed a significant association with BMI. The CDR of SER was affected by both BMI and TP levels. The CDR of ESC was modulated by age, concomitant medications, and renal function.
Conclusion: This study demonstrated that TDM-based individualized medication strategies can support the optimization of antidepressant efficacy. Saliva monitoring requires further validation. Clinicians should adopt dynamic, patient-specific monitoring to enhance precision medicine outcomes in depression management.
Keywords: UPLC-MS/MS, antidepressants, plasma, saliva, therapeutic drug monitoring
1Graduate School of Hebei Medical University, Shijiazhuang, Hebei, 050017, People’s Republic of China; 2Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, Hebei, 050051, People’s Republic of China
Correspondence: Huizhen Wu, Email 13582005982@163.com
Objective: This study aimed to establish a UPLC-MS/MS method for the simultaneous quantification of five antidepressants: venlafaxine (VEN) and its metabolite O-desmethylvenlafaxine (ODV), mirtazapine (MIR), sertraline (SER), escitalopram (ESC), and vortioxetine (VTX) in human plasma and saliva. By analyzing real-world therapeutic drug monitoring (TDM) data, this study aimed to identify key factors influencing drug concentrations thereby optimizing personalized treatment strategies for patients with depression and advancing precision medicine.
Methods: Following liquid-liquid extraction for plasma and protein precipitation for saliva, analyte concentrations were determined using a fully validated UPLC-MS/MS method. Validation included assessments of selectivity, linearity, accuracy, precision, extraction recovery, matrix effects, stability, and dilution integrity. The established method was applied to clinical samples, with further investigation into how clinical factors, including age, BMI, renal function (as measured by GFR), total protein (TP), albumin levels, and concomitant medications, influenced the concentration-to-dose ratio (CDR).
Results: The method demonstrated excellent linearity (5– 500 ng/mL) with all validation parameters meeting acceptance criteria. The established method was successfully applied to analyze 566 plasma and 39 saliva samples. TDM revealed significant variations in target attainment rates among different antidepressants, along with varying degrees of dose-concentration correlations. Multivariate analysis demonstrated that the CDR of VEN + ODV was primarily influenced by age and GFR, while the CDR of MIR showed a significant association with BMI. The CDR of SER was affected by both BMI and TP levels. The CDR of ESC was modulated by age, concomitant medications, and renal function.
Conclusion: This study demonstrated that TDM-based individualized medication strategies can support the optimization of antidepressant efficacy. Saliva monitoring requires further validation. Clinicians should adopt dynamic, patient-specific monitoring to enhance precision medicine outcomes in depression management.
Keywords: UPLC-MS/MS, antidepressants, plasma, saliva, therapeutic drug monitoring